Colby Pharmaceutical Company is a privately held drug company developing both biologic and small molecule drugs for cancer and pain. Colbys lead drugs were all selected for their minimal toxicities and side effects as new molecular entities with unique mechanisms of action to treat or cure patients. Colby Pharmaceutical Companys mission is to develop safe and effective therapeutic drugs, vaccines and companion diagnostics/progostics to help people fight their disease. Colby/MannKind’s immunotherapy programs are built on the observations that administration of immune active compounds by direct intra-lymph node immunization (ILNI), when compared all current standard immunization methods, leads to remarably superior immune responses and immunity. Colby is a clinical stage targeted drug product development company. The company is strategically aligned with leading clinicians and drug development scientists at Stanford University. Colby is accessing data from funded Federal grants, contracts and private investments to develop its small molecule and biologic therapeutic drugs for cancer, infection, inflammation and pain. Colbys lead cancer drugs have unique mechanisms of action and target specific pathways activated in therapy resistant human malignancies with high risk of progression. The Company is focused on clinical development of its lead drugs in patients with prostate and other tumors, along with treatment for leukemia and pain.